Effects of 20 mg oral Δ9‐tetrahydrocannabinol on the olfactory function of healthy volunteers1. (November 2014)
- Record Type:
- Journal Article
- Title:
- Effects of 20 mg oral Δ9‐tetrahydrocannabinol on the olfactory function of healthy volunteers1. (November 2014)
- Main Title:
- Effects of 20 mg oral Δ9‐tetrahydrocannabinol on the olfactory function of healthy volunteers1
- Authors:
- Walter, Carmen
Oertel, Bruno G.
Ludyga, Dagmar
Ultsch, Alfred
Hummel, Thomas
Lötsch, Jörn - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bcp12415-sec-0001" sec-type="section"> <title>Aims</title> <p>Olfactory loss impairs the patient's quality of life. In individualized therapies, olfactory drug effects gain clinical importance. Molecular evidence suggests that among drugs with potential olfactory effects is Δ<sup>9</sup>‐tetrahydrocannabinol (THC), which is approved for several indications, including neuropathic pain or analgesia in cancer patients. The present study aimed at assessing the olfactory effects of THC to be expected during analgesic treatment.</p> </sec> <sec id="bcp12415-sec-0002" sec-type="section"> <title>Methods</title> <p>The effects of 20 mg oral THC on olfaction were assessed in a placebo‐controlled, randomized cross‐over study in healthy volunteers. Using an established olfactory test (Sniffin' Sticks), olfactory thresholds, odour discrimination and odour identification were assessed in 15 subjects at baseline and 2 h after THC administration.</p> </sec> <sec id="bcp12415-sec-0003" sec-type="section"> <title>Results</title> <p>Δ<sup>9</sup>‐Tetrahydrocannabinol impaired the performance of subjects (<italic>n</italic> = 15) in the olfactory test. Specifically, olfactory thresholds were increased and odour discrimination performance was reduced. This resulted in a significant drop in composite threshold, discrimination, identification (TDI) olfactory score by 5.5 points (from 37.7 ± 4.2 to 32.2 ±<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bcp12415-sec-0001" sec-type="section"> <title>Aims</title> <p>Olfactory loss impairs the patient's quality of life. In individualized therapies, olfactory drug effects gain clinical importance. Molecular evidence suggests that among drugs with potential olfactory effects is Δ<sup>9</sup>‐tetrahydrocannabinol (THC), which is approved for several indications, including neuropathic pain or analgesia in cancer patients. The present study aimed at assessing the olfactory effects of THC to be expected during analgesic treatment.</p> </sec> <sec id="bcp12415-sec-0002" sec-type="section"> <title>Methods</title> <p>The effects of 20 mg oral THC on olfaction were assessed in a placebo‐controlled, randomized cross‐over study in healthy volunteers. Using an established olfactory test (Sniffin' Sticks), olfactory thresholds, odour discrimination and odour identification were assessed in 15 subjects at baseline and 2 h after THC administration.</p> </sec> <sec id="bcp12415-sec-0003" sec-type="section"> <title>Results</title> <p>Δ<sup>9</sup>‐Tetrahydrocannabinol impaired the performance of subjects (<italic>n</italic> = 15) in the olfactory test. Specifically, olfactory thresholds were increased and odour discrimination performance was reduced. This resulted in a significant drop in composite threshold, discrimination, identification (TDI) olfactory score by 5.5 points (from 37.7 ± 4.2 to 32.2 ± 5.6, 95% confidence interval for differences THC <italic>vs</italic>. placebo, −7.8 to −2.0, <italic>P</italic> = 0.003), which is known to be a subjectively perceptible impairment of olfactory function.</p> </sec> <sec id="bcp12415-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Considering the resurgence of THC in medical use for several pathological conditions, the present results indicate that THC‐based analgesics may be accompanied by subjectively noticeable reductions in olfactory acuity. In particular, for patients relying on their sense of smell, this might be relevant information for personalized therapy strategies.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of clinical pharmacology. Volume 78:Number 5(2014:Nov.)
- Journal:
- British journal of clinical pharmacology
- Issue:
- Volume 78:Number 5(2014:Nov.)
- Issue Display:
- Volume 78, Issue 5 (2014)
- Year:
- 2014
- Volume:
- 78
- Issue:
- 5
- Issue Sort Value:
- 2014-0078-0005-0000
- Page Start:
- 961
- Page End:
- 969
- Publication Date:
- 2014-11
- Subjects:
- Pharmacology -- Periodicals
Drugs -- Periodicals
615.1 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/bcp.12415 ↗
- Languages:
- English
- ISSNs:
- 0306-5251
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2307.180000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3741.xml